Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MDA-MB-134-VI | HR+ | Luminal | Afatinib | EGFR/HER2 | ErbB | 2.67 | uM | 12206.158 | 0.7817 | 0.6124 | 1.1431 | |
| MDA-MB-134-VI | HR+ | Luminal | Afatinib | EGFR/HER2 | ErbB | 13.3 | uM | 12206.158 | 0.2468 | -0.4118 | 1.1431 | |
| MDA-MB-134-VI | HR+ | Luminal | Afatinib | EGFR/HER2 | ErbB | 66.7 | uM | 12206.158 | 0.0145 | -0.9506 | 1.1431 | |
| MDA-MB-157 | TNBC | Basal B | Afatinib | EGFR/HER2 | ErbB | 0.000171 | uM | 12594.165 | 1.1429 | 1.1889 | 1.4798 | |
| MDA-MB-157 | TNBC | Basal B | Afatinib | EGFR/HER2 | ErbB | 0.000853 | uM | 12594.165 | 1.0096 | 1.0130 | 1.4798 | |
| MDA-MB-157 | TNBC | Basal B | Afatinib | EGFR/HER2 | ErbB | 0.00427 | uM | 12594.165 | 1.0245 | 1.0329 | 1.4798 | |
| MDA-MB-157 | TNBC | Basal B | Afatinib | EGFR/HER2 | ErbB | 0.0213 | uM | 12594.165 | 1.0099 | 1.0134 | 1.4798 | |
| MDA-MB-157 | TNBC | Basal B | Afatinib | EGFR/HER2 | ErbB | 0.107 | uM | 12594.165 | 1.0521 | 1.0698 | 1.4798 | |
| MDA-MB-157 | TNBC | Basal B | Afatinib | EGFR/HER2 | ErbB | 0.533 | uM | 12594.165 | 1.0092 | 1.0125 | 1.4798 | |
| MDA-MB-157 | TNBC | Basal B | Afatinib | EGFR/HER2 | ErbB | 2.67 | uM | 12594.165 | 0.6305 | 0.4644 | 1.4798 | |
| MDA-MB-157 | TNBC | Basal B | Afatinib | EGFR/HER2 | ErbB | 13.3 | uM | 12594.165 | 0.0119 | -0.9001 | 1.4798 | |
| MDA-MB-157 | TNBC | Basal B | Afatinib | EGFR/HER2 | ErbB | 66.7 | uM | 12594.165 | 0.0074 | -0.9272 | 1.4798 | |
| MDA-MB-175-VII | HR+ | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.000171 | uM | 12126.158 | 1.0391 | 1.1323 | 0.5992 | |
| MDA-MB-175-VII | HR+ | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.000853 | uM | 12126.158 | 0.7292 | 0.1806 | 0.5992 | |
| MDA-MB-175-VII | HR+ | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.00427 | uM | 12126.158 | 0.9266 | 0.7610 | 0.5992 | |
| MDA-MB-175-VII | HR+ | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.0213 | uM | 12126.158 | 0.7237 | 0.1660 | 0.5992 | |
| MDA-MB-175-VII | HR+ | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.107 | uM | 12126.158 | 0.2617 | -0.7865 | 0.5992 | |
| MDA-MB-175-VII | HR+ | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.533 | uM | 12126.158 | 0.1957 | -0.8686 | 0.5992 | |
| MDA-MB-175-VII | HR+ | Luminal | Afatinib | EGFR/HER2 | ErbB | 2.67 | uM | 12126.158 | 0.0565 | -0.9835 | 0.5992 | |
| MDA-MB-175-VII | HR+ | Luminal | Afatinib | EGFR/HER2 | ErbB | 13.3 | uM | 12126.158 | 0.0161 | -0.9980 | 0.5992 | |
| MDA-MB-175-VII | HR+ | Luminal | Afatinib | EGFR/HER2 | ErbB | 66.7 | uM | 12126.158 | 0.0079 | -0.9994 | 0.5992 | |
| MDA-MB-361 | HER2amp | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.000171 | uM | 12379.165 | 1.0129 | 1.0733 | 0.3550 | |
| MDA-MB-361 | HER2amp | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.000853 | uM | 12379.165 | 1.0081 | 1.0458 | 0.3550 | |
| MDA-MB-361 | HER2amp | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.00427 | uM | 12379.165 | 0.9302 | 0.6312 | 0.3550 | |
| MDA-MB-361 | HER2amp | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.0213 | uM | 12379.165 | 0.7859 | 0.0144 | 0.3550 |